Crossmark

Neoantigen prediction and the need for validation

Published Online: 2017-09-11

Published Print: 2017-09

Authors

Vitiello, Antonella

Zanetti, Maurizio
License Information

Text and Data Mining valid from 2017-09-01

Version of Record valid from 2017-09-01
More Information

Article History

First Online: 11 September 2017

Competing interests

: A.V. is the CEO of PersImmune Inc., a biotech company focused on the development of personalized immunotherapy.

Document is current